Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
JA JAZZ Jazz Pharmaceuticals plc FY ended Apr 15, 2026 | $244.54 | $15.87B | $18.75B | $4.27B | $69.38M | -$356.15M | -41.87x | 3.72x | 58.20x |
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
PR PRGO PERRIGO Co plc FY ended Feb 24, 2026 | $14.48 | $2.01B | $4.70B | $4.25B | -$781.50M | -$1.43B | -1.41x | 0.47x | — |
HR HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $39.21 | $2.28B | $1.90B | $868.45M | $262.93M | $158.69M | 14.47x | 2.63x | 6.82x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 30.42x | 3/4 | $10.38B | $84.79 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 2.59x | 4/4 | $1.53B | $12.46 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -23.28x | 4/4 | -$4.99B | — | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
JA JAZZ Jazz Pharmaceuticals plc FY ended Apr 15, 2026 | $244.54 | $15.87B | $18.75B | $4.27B | $69.38M | -$356.15M | -41.87x | 3.72x | 58.20x |
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
PR PRGO PERRIGO Co plc FY ended Feb 24, 2026 | $14.48 | $2.01B | $4.70B | $4.25B | -$781.50M | -$1.43B | -1.41x | 0.47x | — |
HR HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $39.21 | $2.28B | $1.90B | $868.45M | $262.93M | $158.69M | 14.47x | 2.63x | 6.82x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 30.42x | 3/4 | $10.38B | $84.79 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 2.59x | 4/4 | $1.53B | $12.46 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -23.28x | 4/4 | -$4.99B | — | Peer averages are not economically meaningful for this method. |
